Stephens analyst Chris Cooley believes investors should take advantage of the recent pullback in Glaukos (GKOS) shares, arguing that the company's existent new product pipeline plus the potential total addressable market expansion from the company's planned Avedro (AVDR) acquisition "more than merits" a roughly 25% relative valuation premium. Combining the companies results in a roughly 450 basis points increase to reported growth in calendar 2021 before factoring in the opportunity for potential revenue synergies, contributions from planned new products, expanded indications for use or geographic expansion, said Cooley, who maintains his $95 price target and Overweight rating on Glaukos shares.